Oncotarget is an online medical journal that was started in 2010 to enlighten the public on various things to do with oncology. Impact Journals are the publishers of the journal. It is peer reviewed, and the information provided in the papers published is accurate and of very high quality. The journal’s quality standards are upheld by their team of editors which is led by Mikhail Blagosklonny. They review the articles sent by authors, check if the references are credible, and recommend changes to be made so that the end product is a quality article that will be of help to the readers. Oncotarget publishes twice weekly.
It used to publish only once a week but due to demand, it increased the frequency to two times a week. The articles published are used by different groups of people including students and other researchers. The main focus of the journal is on oncology, and initially, they only published articles on various aspects of oncology. But today, Oncotarget publishes articles on various fields of medicine including neuroscience, metabolism, cardiology, pharmacology and cell biology among others.The journal is free and accessible to anyone who is interested, and the papers published can be printed upon request.
Oncotarget gives researchers a chance to publish their work. Other journals might reject some papers for various reasons but Oncotarget reviews the papers presented and helps the authors improve them it to meet their standards so that their papers can be published. Rejecting such work might deny the public access to important findings that might lead to important developments in various fields of medicine.Oncotarget is one of the leading oncology journals. In fact, in 2016, it was recognized as the best oncology journal by Total Documents. The members of the Oncotarget team are highly qualified scientists are researchers by their own right. In fact, a few members of the Oncotarget team have received the coveted Breakthrough Prize over the past few years. On top of all these, the journal abides by the highest ethical standards.
Oncotarget has proven to be a very important resource for students and other scientists. This is because access to most research papers may be highly restricted and expensive, especially for students. It is therefore no wonder why it one of the leading journals on oncology.
Mikhail Blagosklonny is a great Oncologist who is revered for his relentless efforts in the cancer research field. Mikhail background training places him at a good place to tackle his roles meticulously. He is a Ph.D. holder in experimental medicine and cardiology, earned from the First Pavlov State Medical University of St. Petersburg the same institute that he got his M.D in internal medicine.
Mikhail’s first role was in 2002 at the New York Medical College strategically positioned in Valhalla, New York where he worked as an Associate Professor. He then undertook a position at the Ordway Research Institute as a Senior Scientist before an Oncology Professor role beckoned at the Roswell Park Cancer Institute in 2009. His expertise over the years has shaped him to be the great professor that he is currently.
Know more: http://gettingstronger.org/tag/mikhail-blagosklonny/
Besides his normal work, Mikhail Blagosklonny has written many articles about medical research, such as the hyperfunction theory, cell cyclotherapy, and chemotherapeutic engineering among others. He has written 300 unique and well-formatted research articles, reviews, and books contribution published in his name. Mikhail Blagosklonny holds the role of the Chief Editor for Oncotarget and Cell cycle as well as an associate editor for PLOS ONE, cancer biology, and therapy, the American Journal of Pathology, and International Journal of Cancer. He is also an official member and key decision-maker of the editorial board for Cell Death and Differentiation.
Involvement in Cancer Research
Mikhail’s interest in cancer research is driven by his love for humanity and the desire to see the world being free of cancer. His efforts run deep and wide in this sector starting with his research in Biogerontology that studies about protecting healthy cells from damage through the use of anti-aging drugs and therapies. In one of his research, Mikhail Blagosklonny came up with a theory that shows the role that Tor Signaling plays in aging and cancer. He suggested the use of a cancer drug named rapamycin in treatment and possibly prolonging life. His other research varies from clinical to cellular and molecular biologies, such as oncogenesis, tumor suppressors, apoptosis, cell cycle, anticancer therapeutics, mitosis, signal transduction, and drug resistance for normal cells. Visit ResearchGate.Net to learn more about Mikhail’s latest work.